BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T042027
CREATED:20240103T125432Z
LAST-MODIFIED:20240103T131021Z
UID:38428-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:5th TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:The 5th TCR-based Therapies for Solid Tumors Summit returns is back as the exclusive gathering where TCR pipelines take center stage. It serves as the premier platform for networking with biopharma industry leaders dedicated to expediting the clinical and commercial development of TCR-based therapeutics. \nThis summit serves as the epicenter for exploring these transformative advancements\, poised to showcase the long-term efficacy of TCR therapies in the treatment of solid tumors\, marking a monumental milestone in the field’s evolution. \nThis is your opportunity to accelerate next generation TCR engineering\, enhance target identification\, & improve solid tumor persistence to transform clinical & scalable development for patients in need. Join TScan Therapeutics\, Marengo Therapeutics\, T-Cypher Bio and more to gain invaluable insights into the future of TCR-based therapies. \nFind out more here: https://ter.li/f8jhfw
URL:https://www.pharmajournalist.com/event/5th-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240422
DTEND;VALUE=DATE:20240425
DTSTAMP:20260515T042027
CREATED:20240125T115520Z
LAST-MODIFIED:20240125T115520Z
UID:38573-1713744000-1714003199@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices East Coast Conference and Exhibition
DESCRIPTION:SAE Media Group’s 11th Annual Pre-Filled Syringes East Coast Conference will return to Boston in April 2024 to bring you the latest advances in the combination product drug delivery space. The 2024 conference will be bigger and better than ever\, bringing you 3 days of expertise\, comprising of a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference with morning keynote plenaries and parallel afternoon topic streams addressing the industry’s hottest topics through case studies and industry insights. \nThis event will not only bring you key insights needed to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in April 2024! \nWhy attend: \n\n3 full days of networking opportunities\n40+ presentations with 75% of speakers from the top 20 big pharma companies\nThe agenda has been curated by an advisory board of big pharma and biotech opinion leaders providing expertise focused on device development\, regulatory affairs and quality\nAccess a focus day and 4 dedicated streams addressing the hottest topics in the industry\n\nThis year’s agenda has been validated by our 2024 advisory board: \nJohn Schalago\, Executive Director\, Senior Global Program Director\, Novartis\nKhaudeja Bano\, Vice President\, Combination Product Quality\, Amgen\nJames P. Wabby\, Global Head\, Regulatory Affairs – Emerging Device Technologies and Combination Products\, AbbVie\nMark DeStefano\, Director\, Combination Products and Devices R&D\, Teva\nMichael Song\, Director\, Drug Product Development\, Moderna \nWhat you will gain: \n\nCollaborate with pharma\, biotech and device developers across 3 full days on the latest trends\, advancements and challenges within the pre-filled syringe and injectable device market\nHear about new technological advances for challenging to delivery drugs such as large volume\, highly viscous and lyophilised formulations with case studies on wearable injectors and more\nUnderstand the latest regulatory requirements from experts surrounding combination products and engage in opportunities for collaboration and needs for advancing innovation in the field with an advisory board fireside chat\nGain insight into how big pharma is incorporating sustainable approaches into drug device design and lifecycle management\nDelve into the growing potential of digital health to improve patient experience and treatment\, and the challenges facing its implementation\nExamine how container and packaging development can support the ever-evolving innovations drug development\, including case studies on CCIT in deep-cold storage and formulator perspectives\n\nTo know more visit: www.pfsamericas.com/PharmaJournalist-Event-Listing
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-east-coast-conference-and-exhibition/
LOCATION:Boston\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240416
DTEND;VALUE=DATE:20240419
DTSTAMP:20260515T042027
CREATED:20240213T101859Z
LAST-MODIFIED:20240213T101859Z
UID:38680-1713225600-1713484799@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Muscular Disorders
DESCRIPTION:Discover the forefront of gene therapy at the 4th Gene Therapy for Muscular Disorders Summit (April 16-18\, Boston). Following the groundbreaking approval of Sarepta’s DMD gene therapy in June 2023\, our April 2024 gathering explores key challenges in translating research into clinical breakthroughs. With a sharp focus on safety and efficacy\, we unite experts to advance transformative treatments for muscular disorders lacking viable options. Join us to propel innovation forward and make a tangible impact on patient care. This is your opportunity to shape the future of muscular disorder treatments in just one event. \nWant to learn more? Check out the event guide here: https://ter.li/cjxppp
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-muscular-disorders/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240416
DTEND;VALUE=DATE:20240419
DTSTAMP:20260515T042027
CREATED:20240111T102149Z
LAST-MODIFIED:20240326T141147Z
UID:38478-1713225600-1713484799@www.pharmajournalist.com
SUMMARY:4th Fc-Mediated Function Summit
DESCRIPTION:Discover & Shape the Future of Biologics & Antibody Therapies at the 4th Fc-Mediated Function Summit \nFINAL 5 PASSES REMAINING – Register Now at https://ter.li/g5st7q \nAt the intersection of groundbreaking research\, clinical innovation\, and collaborative networking\, the 4th Fc-Mediated Function Summit stands as a beacon for advancing the frontier of FcRn\, FcγR\, and IgG therapeutics. Our mission is to supercharge molecular development\, elevate clinical utility\, and explore novel therapeutic applications through a comprehensive understanding of targets and biology. \nIn a landscape where clinical data is expanding\, and partnerships like the Argenx-Genmab powerhouse exemplifying the potential of antibody therapies\, the spotlight on biologics Fc modulation as a therapeutic target has been more intense than ever. The 4th Fc-Mediated Function Summit continues to be at the forefront of this movement\, uniting experts and enthusiasts alike. \nKey Highlights: \nTargeting FcRn & FcγR Biology: \nUnlock the secrets of molecular engineering and real-world clinical outcomes by focusing on the critical targets – FcRn and FcγR. Gain insights into the intricacies of their biological pathways\, and understand how molecular modifications can translate into tangible clinical benefits. \nUnrivaled Content: \nAs the only conference dedicated exclusively to FcRn\, this meeting will comprehensively cover the landscape. Attendees can expect to be immersed in cutting-edge research\, the latest advancements\, and a holistic understanding of the subject matter. This focus ensures that participants are at the forefront of knowledge and equipped with insights that are not diluted by unrelated topics\, setting this summit apart as a beacon of specialized expertise. \nExceptional Networking: \nForge meaningful connections with a diverse cohort of professionals spanning immunology\, antibody engineering\, pharmacology\, toxicology\, and immuno-oncology. The summit provides a unique opportunity to engage with 80+ peers\, facilitating cross-disciplinary partnerships and knowledge exchange.
URL:https://www.pharmajournalist.com/event/4th-fc-mediated-function-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240416
DTEND;VALUE=DATE:20240419
DTSTAMP:20260515T042027
CREATED:20231215T122902Z
LAST-MODIFIED:20231215T123125Z
UID:38368-1713225600-1713484799@www.pharmajournalist.com
SUMMARY:3rd ADC Analytical Development Summit
DESCRIPTION:The 3rd ADC Analytical Development Summit is your only industry-dedicated meeting providing you with the key insights to ensure you are developing a high-quality ADC product within regulatory boundaries. \nNext year’s program promises to give you even more focused content to better quantify DAR and drug distribution\, overcome species separation challenges\, and better utilize impurity assays to measure free-linker drug and process-related impurities. \nGet an exclusive sneak peek of the agenda here. \nNot only is this meeting packed with technical content that will allow you to influence\, gain a deeper understanding\, and improve product quality\, but it will also give you the opportunity to interact with industry experts including: \n\nNailing Zhang\, Lead Biologist\, FDA\nLinda Nelson\, Executive Director\, RA-CMC\, Daiichi Sankyo\nDavid Lee\, Executive Director\, Analytical Chemistry\, Mersana Therapeutics\nChris Woods\, Scientist\, Analytical Development\, Seagen\nMadhumati Mukherjee\, Senior Scientist\, AstraZeneca\nDengyun (Daisy) Sun\, Principal Scientist\, Cell Based Sciences\, Merck & Co.\nYan-Hui Liu\, Director\, Analytical Development\, GlaxoSmithKline\n\n…and many more! \nSee the full speaker lineup and agenda sessions here. \nWe hope you can join us to network with like-minded colleagues and scientists and have the in-depth technical conversations needed to address the common analytical bottlenecks in ADC development.
URL:https://www.pharmajournalist.com/event/3rd-adc-analytical-development-summit/
LOCATION:Hilton Boston Bay Back\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240409
DTEND;VALUE=DATE:20240412
DTSTAMP:20260515T042027
CREATED:20240116T093630Z
LAST-MODIFIED:20240116T093700Z
UID:38503-1712620800-1712879999@www.pharmajournalist.com
SUMMARY:Measuring Patient Engagement Summit
DESCRIPTION:The Measuring Patient Engagement Summit is the definitive conference for practical answers. This event will act as the honeypot gathering for leading patient engagement experts to share their latest experiences of how they are successfully measuring patient engagement to: inform decision making in improving patient engagement\, quantify the impact of patient engagement on recruitment and retention\, and ensure the most meaningful outreach to patients and advocacy groups. \n \nJoin 70+ Chief Patient Officers\, Patient Engagement leaders and Patient Advocacy experts\, from esteemed pharmaceutical and biotech companies\, such as Novartis\, Otsuka\, Boehringer Ingelheim\, AstraZeneca and many more\, to establish a roadmap to quantify the success of your patient engagement work. \n  \nCheck out the full event guide now: https://ter.li/cqba4m
URL:https://www.pharmajournalist.com/event/measuring-patient-engagement-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240330
DTSTAMP:20260515T042027
CREATED:20240103T114154Z
LAST-MODIFIED:20240103T114154Z
UID:38420-1711411200-1711756799@www.pharmajournalist.com
SUMMARY:7th Gene Therapy for Rare Disorders Summit
DESCRIPTION:This past year has seen more gene therapies approved by the FDA than the previous five years combined\, and almost triple the number of clinical trials in gene therapy have been initiated in H1 of 2023 compared to the same time frame in the previous year. \nTo maximize the value of your late-stage gene therapy assets\, the 7th Gene Therapy for Rare Disorders Summit is returning to tackle head-on the significant clinical\, manufacturing\, regulatory\, and commercial challenges facing gene therapy programs today. \nBringing together key figures from industry\, regulatory bodies\, patient non-profits\, payers\, and key service providers\, this is the field’s foremost meeting for collectively progressing rare gene therapy programs into and through the clinic. \nJoin us to leverage essential insights from over 300 peers from leading biopharma companies with direct experience in driving gene therapies through the clinic and into the market. Keep your finger on the pulse\, form connections with top decision-makers\, and address your specific clinical\, manufacturing\, regulatory\, and commercial bottlenecks to safeguard against costly delays and progress your gene therapies through the pipeline quickly and safely. \nTo know more visit: https://ter.li/x4qqur
URL:https://www.pharmajournalist.com/event/7th-gene-therapy-for-rare-disorders-summit/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240328
DTSTAMP:20260515T042027
CREATED:20231201T114649Z
LAST-MODIFIED:20231201T143620Z
UID:38253-1711411200-1711583999@www.pharmajournalist.com
SUMMARY:Pharma USA 2024
DESCRIPTION:Accelerate patient value. Pioneer healthcare’s transformation.  \nHealthcare reforms are finally paving the way to affordable access to medicines\, yet this progress threatens the development of future life-saving therapies. The moment is now to prove ourselves as a trusted industry ally and the ultimate safe harbor for patients. \nThe key? Delivering aligned value to HCPs\, patients\, payers and regulators. \nSpeed and scale is non-negotiable. Those afraid to accelerate will be left behind. We must adapt to evolving payer needs\, empower HCPs with crucial insights\, bridge regulatory gaps and co-create with patients. Only then will we achieve exceptional outcomes. \nReuters Events: Pharma USA 2024 is where senior pharma executives from Commercial\, Marketing\, Medical Affairs\, RWE\, Market Access\, Patient Engagement\, as well as key stakeholders\, will come together to map out how they can deliver value to overcome the challenges that are hindering scientific innovation. \nJoin over 1\,200 of North America’s pharma pioneers\, leading solutions provider\, and patient advocates to sharpen short-term strategy and unite for a long-term future to exceed stakeholder desires across the value chain. \nTo know more visit: https://bit.ly/3GpdsrU
URL:https://www.pharmajournalist.com/event/pharma-usa-2024/
LOCATION:Pennsylvania Convention Center\, 1101 Arch Street\, Philadelphia\, PA\, 19107\, United States
ORGANIZER;CN="Reuters Events":MAILTO:Kana.Hutton@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240329
DTSTAMP:20260515T042027
CREATED:20231107T111306Z
LAST-MODIFIED:20231107T111306Z
UID:38097-1711411200-1711670399@www.pharmajournalist.com
SUMMARY:5th Glioblastoma Drug Development Summit
DESCRIPTION:The 5th Glioblastoma Drug Development Summit is the only industry led forum for large pharma\, biotech\, neuro-oncologists and academic KOLs to unite alongside a dedicated panel of investors under the common goal to breakthrough GBM barriers to accelerate the practical translation and clinical development of emerging therapeutics for glioblastoma and CNS tumor patients. \nDiscover innovative approaches to surpassing the blood-brain barrier to unlock previously uncovered therapeutic potential\, keep ahead of the latest clinical trial design rationale and navigate the regulatory landscape for novel combination therapies with actionable insights to improve clinical success. \nWith promising clinical readouts from a range of therapeutic modalities\, novel drug targets emerging and positive advances in state-of-the-art technologies like sonodynamic therapy\, there is more potential than ever before to be unlocked within the GBM space. \nTo elevate your current standards\, join this unique collaboration between industry giants such as Novartis\, pioneering biotechs such as Day One Biopharmaceuticals\, world-renowned academics and investors. Embrace positive clinical outcomes alongside a dedicated community committed to defeating GBM/CNS tumors and transforming lives. \nAccess the complete agenda here including a packed pre-workshop conference day\, panel discussions\, poster sessions and important networking opportunities.
URL:https://www.pharmajournalist.com/event/5th-glioblastoma-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240325
DTEND;VALUE=DATE:20240328
DTSTAMP:20260515T042027
CREATED:20231120T150249Z
LAST-MODIFIED:20231120T150249Z
UID:38186-1711324800-1711583999@www.pharmajournalist.com
SUMMARY:5th Supply Chain & Logistics for Cell Therapies Summit
DESCRIPTION:As the cell therapy field rapidly expands\, keeping ahead of the race by creating a visible and robust supply chain has never been more critical to ensure you have the skills and strategy to develop into the next stage of your pipeline. \nJoin us at the 5th Supply Chain & Logistics for Cell Therapies Summit in Boston from March 25-27th. This summit will bring together logistics and clinical operations experts to establish standardized best practices in planning\, communication and assist companies in scaling up to consistently deliver cell therapies safely\, on time\, and in a cost-effective process. \nSeize the opportunity to enhance your expertise in cell therapy logistics by connecting with leaders in clinical operations\, including esteemed companies like Beam Therapeutics\, Lovance\, Arcellx\, Jassen Pharmaceuticals\, and more. \nDownload the event guide to learn more: https://ter.li/d6jto3
URL:https://www.pharmajournalist.com/event/5th-supply-chain-logistics-for-cell-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240325
DTEND;VALUE=DATE:20240328
DTSTAMP:20260515T042027
CREATED:20231115T103534Z
LAST-MODIFIED:20231115T103534Z
UID:38132-1711324800-1711583999@www.pharmajournalist.com
SUMMARY:6th Neuroimmunology Drug Development Summit
DESCRIPTION:Neuroimmunology targets in neurodegeneration are hotter than ever. Capturing biopharma’s latest research spanning discovery to early clinical development\, the 6th Neuroimmunology Drug Development Summit is the industry-choice\, comprehensive forum dedicated to translating neuroinflammatory-targeted therapeutics into clinical trials. \nWhat are the top features to look forward to in 2024? \n\nDoubled pre-conference workshop content\, with 6 deep-dive sessions tailored to your discovery biology and translational expertise led by neuroimmunology leaders from Lundbeck\, Sanofi\, Merck\, Regeneron\, and more\nAgenda content spotlighted neurodegeneration – including TREM2 clinical data updates and breaking down trial design and rationale with Alector and Vigil Neuroscience\nNew case studies beyond microglia\, with sessions spearheading astrocyte function and therapeutic intervention from Sanofi\, IMNEWRUN\, and UCL\nBrand-new content on immunocompetent brain organoids to recapitulate and investigate complex neuroimmune interactions with Roche and Herophilus\nIt is the biggest and most comprehensive program to date\, with 38+ industry and academic speakers\, including new presenting companies Eisai\, EMD Serono\, Ventus Therapeutics\, PTC Therapeutics\, and Inflammasome Therapeutics\n\nUniting 100+ all-star leaders across industry and academia\, this is the must-attend forum for anyone working on treatments targeting neuroinflammation across neurological indications and looking to accelerate their candidates into the clinic in 2024. \nTo know more visit: https://ter.li/wb3bhh
URL:https://www.pharmajournalist.com/event/6th-neuroimmunology-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T042027
CREATED:20231207T115623Z
LAST-MODIFIED:20231207T115623Z
UID:38307-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:2nd Targeted Intracellular Delivery Summit
DESCRIPTION:Step into the 2nd Targeted Intracellular Delivery Summit\, a thrilling exploration of cutting-edge advancements in drug delivery. This year\, we redefine possibilities\, venturing beyond traditional boundaries with a focus on cellular biology and intracellular mechanisms. \nOptimize drug delivery\, overcome endosomal challenges\, and expand therapies beyond the liver with in-depth case studies and a Pre-Conference Workshop Day. Gain insights into targeted cell interventions for cancer and autoimmune diseases\, re-thinking innovative delivery platforms and strategies for cargo delivery into novel targets. \nEngage in transformative discussions and exclusive case studies with industry giants like Sanofi\, Merck & Co\, Sana Biotechnology\, and Capstan Therapeutics. Uniting C-Level Executives\, Researchers\, and Directors\, this event is the only industry-led forum focused on cellular mechanisms to enable targeted intracellular drug delivery. Addressing challenges in compartmentalization and endosomal escape\, it aims to optimize therapeutic efficacy and minimize toxicity. \nJoin us in March 2024 to delve into the forefront of intracellular targeting\, where innovation meets expertise to propel your drug pipelines toward unprecedented success. \nTo know more visit: https://ter.li/p72w9g
URL:https://www.pharmajournalist.com/event/2nd-targeted-intracellular-delivery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T042027
CREATED:20231207T114720Z
LAST-MODIFIED:20231207T114720Z
UID:38297-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:4th Wet AMD & Diabetic Eye Disease Drug Development Summit
DESCRIPTION:The 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit is returning to Boston this upcoming March to unite 70+ industry-based retinal vascular experts from the likes of Bayer\, Boehringer Ingelheim\, Genentech\, Novartis and OcuTerra\, at the only industry-dedicated forum to transform the potential of treatment of chronic\, sight-threatening retinal vascular diseases to improve patient outcomes. \n \nNew additions for 2024 include: \n\nFresh perspectives from the new companies speaking at the 2024 meeting including Aviceda Therapeutics\, Bayer\, Boehringer Ingelheim\, OcuTerra\, Novartis\, Genentech\, and Adverum Biotechnologies\n16+ brand-new speakers out of the 18+ speaker faculty consisting of industry experts and academic leaders working on preclinical models\, choroidal neovascularization\, retinal inflammation\, durable drug delivery to the retinal vascular system and more\nRobust new content focusing on industry-specific topics such as new targets\, in vivo and in vitro models\, retinal imaging and clinical biomarkers and new modalities for retinal and choroidal neovascularization\n\nTo know more visit: https://ter.li/cjnu7k
URL:https://www.pharmajournalist.com/event/4th-wet-amd-diabetic-eye-disease-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T042027
CREATED:20231207T113944Z
LAST-MODIFIED:20231207T113944Z
UID:38292-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:4th Operationalize Expanded Access Programs Summit
DESCRIPTION:Following the increasing interest in access to investigational medicines from patients\, the harmonization of guidance and research on the value of expanded access programs witnesses a critical rise. \nBack in Boston as the only industry forum defining global regulations for EAP and your definitive networking opportunity to connect with managed access teams from other leading and new companies that are immersing themselves in this evolving field of opportunity and life-changing support. \nReunite with 120+ industry experts setting up and leading EAPs at the 4th Operationalize Expanded Access Programs Summit and gain practical take aways on how to construct a reliable system\, define a clear exit strategy\, understand updated local and global regulations\, and determine the role of real-world data to optimize the operationalization of your EAP. This is your one-stop shop to capturing industry’s latest case studies in setting up a program globally\, reaching physicians and patients\, collecting real-world data\, and maximizing vendor selection to improve the operationalization of EAP and streamline access to life-changing therapies. \nWhat’s New for 2024? \n\nA deep dive into the country-level challenges and regulators’ requirements along with the best practices for labelling\, shipping\, and reporting to deliver a successful project across the US\, LATAM and Middle East with UCB\, GSK\, Novartis\, Biogen\, Sanofi\, SpringWorks Therapeutics and Day One Biopharmaceuticals\nA delve into the experiences and perspectives of physicians to better understand their pain points and how they become aware of EAPs to strengthen these relationships and move the field forward with the University of Michigan and Riboscience\nAn active discussion into the role of real-world data and the setup of an EAP through value-based organisations to obtain a large community of patients and carry this out with ease with AstraZeneca\n\nDon’t miss out on your opportunity to be amongst physicians\, patients and passionate EAP and clinical supply experts from Novartis\, Daiichi Sankyo\, GSK\, AstraZeneca\, Gilead\, Biogen\, Sanofi\, Eli Lilly\, Regeneron\, and many more to discover novel strategies in overcoming operational hurdles and deliver life-saving treatments to patients more efficiently. \nTo know more visit: https://operationalize-eap.com/
URL:https://www.pharmajournalist.com/event/4th-operationalize-expanded-access-programs-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T042027
CREATED:20231116T104232Z
LAST-MODIFIED:20231116T104232Z
UID:38153-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:3rd Cell Therapy Potency Assay Summit
DESCRIPTION:In the dynamic cell therapy landscape\, the challenge of potency assay development looms large\, as exemplified by clinical holds experienced by Mesoblast and Verve Therapeutics in recent years. \nAt the 3rd Cell Therapy Potency Assay Summit\, we bring together over 120 analytical\, quality control\, and regulatory experts including esteemed organizations like BMS\, J&J\, Atara Biotherapeutics\, Fate Therapeutics\, Health Canada. The summit will address these pressing concerns with the goal to collaboratively design more effective potency assays that not only streamline regulatory approval but also reduce hold times significantly. \nJoin us and leave equipped with industry insights that enable you to develop practical and reproducible assays\, providing a deeper understanding of your cell therapy products. \nFind out more here: https://ter.li/e448ls
URL:https://www.pharmajournalist.com/event/3rd-cell-therapy-potency-assay-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T042027
CREATED:20231108T095535Z
LAST-MODIFIED:20231109T143458Z
UID:38106-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:6th CKD Drug Development Summit
DESCRIPTION:The Definitive Industry Forum for CKD Drug Development \nAdvance More Personalized Therapies for Rare & Common Kidney Diseases \nThe 6th CKD Drug Development Summit is the definitive forum for KOLs\, industry experts\, and regulators to bring kidney innovation onto the next generation of drug development\, uniting 200+ biopharma stakeholders\, from scientific research to clinical development and outcomes\, across three days of concentrated discussion. \nFrom uncovering the genetic architecture of specific CKD subgroups and revolutionizing translatable models of renal pathophysiology\, to breaking new ground in CKD trial design and implementing new therapies into the treatment paradigm\, join Novo Nordisk\, Boehringer Ingelheim\, Eli Lilly\, AstraZeneca\, the FDA\, Regeneron\, Novartis and more to collaborate and drive progress of precision medicine and reinvent the landscape of rare and common kidney disease treatments.
URL:https://www.pharmajournalist.com/event/6th-ckd-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240318
DTEND;VALUE=DATE:20240321
DTSTAMP:20260515T042027
CREATED:20240213T100720Z
LAST-MODIFIED:20240213T100720Z
UID:38674-1710720000-1710979199@www.pharmajournalist.com
SUMMARY:9th Innate Killer Summit 2024
DESCRIPTION:“The translational impact and nature of the work that was being presented were outstanding. You get a lot of insights from your peers regarding their experience interacting with the regulatory agencies” – ONK Tx \nThe 9th Innate Killer Summit is designed for experts striving to realize the clinical potential of NK–based therapies from early discovery to later stages in the clinic through 3 dedicated tracks of content: Pre-clinical\, Clinical Translation\, CMC & Process Development. \nSpecifically focussing on advancing NK engager\, bispecific\, cell therapy\, and combination therapy approaches to improve the clinical durability and streamlining manufacturing. Come together with industry experts to brainstorm best approaches to enhance efficacy and persistence as well as reduce the cost of production. \nCollaborating closely with pioneers such as Dan Kaufman\, Evren Alici\, and industry experts from Zelluna Immunotherapy\, Artiva Biotherapeutics\, Affimed\, Sanofi\, Immunity Bio\, Cytovia (to name a few!) to ensure the critical priorities of the field are captured. Join to gain practical takeaways for novel techniques in engineering NK cells while preserving cell fitness\, best practice clinical trial design methods\, benefits of feeder-free cell expansion and many more! \nRanging from a jam-packed pre-conference workshop day with 6 different workshops and a bootcamp ranging from preclinical to CMC and process development. Also up for offer are 10+ plenary talks across the main conference days where experts will guide you through the current cell therapy landscape\, an industry leaders annual briefing\, a range of clinical data presentations\, and an investors panel!
URL:https://www.pharmajournalist.com/event/9th-innate-killer-summit-2024/
LOCATION:San Diego Marriott Del Mar\, 11966 El Camino Real\, San Diego\, CA\, 92130\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240318
DTEND;VALUE=DATE:20240321
DTSTAMP:20260515T042027
CREATED:20231123T125135Z
LAST-MODIFIED:20231123T125201Z
UID:38203-1710720000-1710979199@www.pharmajournalist.com
SUMMARY:7th Antigen-Specific Immune Tolerance Drug Development Summit
DESCRIPTION:Returning for the seventh year\, the 7th Antigen-Specific Immune Tolerance Summit (March 18 – 20\, 2024 | Boston\, MA) will lean into the industry’s key challenges from details of T-cell assays in preclinical and larger clinical studies; to pioneering CAR-Treg\, mRNA-LNP\, biologic\, peptide\, approaches and updates on proof-of-concept and ongoing clinical programs. This is the highest value meeting on the immune tolerance community’s conference calendar. \nThis is your comprehensive guide to define your pipeline and therapeutic development strategy for 2023\, delve into your opportunity to create tolerizing\, curative\, strategies for autoimmunity\, and tap into your tolerance strategy to tackle immunogenicity and transform the biologic landscape. Network with large pharma scouts\, industry super-giants\, and biotech pioneers to build meaningful partnerships and gather insights beyond the literature. \nExpect to be involved in interactive discussions on: \n\nTackle antigen-selection and deepen your understanding of the role of T-cells\, B-cells and T-regs in immune tolerance evaluate strategies and technologies in complex heterogenous disease settings with COUR Pharmaceuticals and Pfizer.\nBuild the biomarker toolbox and engage in discussions around the true markers of ‘tolerance’ for practical tolerance strategies and markers for determinants of efficacy\, patient selection\, and therapeutic durability with Takeda\, University of Pittsburgh\, Imcyse\, and Anokion\nAssess toxicity and durability of tolerance therapeutics using preclinical models to inform the frequency of administration and the persistence or loss of tolerance over time with Toleranzia and University of Helsinki\nEvaluate delivery technologies and novel approaches including CAR-Treg\, mRNA-LNP\, biologics\, and more to propel tolerizing therapies through proof-of-concept to the clinic with Sonoma\, Moderna\, and Integrated Nanotherapeutics\nHarness mechanistic models and autoimmune disease models to highlight efficacious tolerance induction across diseases including Celiac\, Type 1 Diabetes\, Multiple Sclerosis\, Rheumatoid Arthritis\, and more with GRO Bioscience\, RheumaGen\, NexImmune\, and Parvus Therapeutics\n\nJoin 110+ autoimmune and immunologist scientists\, corporate strategists\, and large pharma scouts at this timely and comprehensive summit set to unite the immune tolerance field. From innovative\, start-up biotechs to big pharma super giants\, this is your unique opportunity to discuss advancing efficacious antigen- and drug-specific tolerance approaches to patients in need. \nDownload the full agenda here to see our full speaker faculty\, 3-day agenda and audience breakdown: https://ter.li/7teig8
URL:https://www.pharmajournalist.com/event/7th-antigen-specific-immune-tolerance-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240312
DTEND;VALUE=DATE:20240316
DTSTAMP:20260515T042027
CREATED:20231215T122622Z
LAST-MODIFIED:20231215T124912Z
UID:38363-1710201600-1710547199@www.pharmajournalist.com
SUMMARY:14th World ADC London 2024
DESCRIPTION:We find ourselves at the cutting edge of oncology innovation\, with the ADC field booming with excitement due to the constant eflux of clinical progress and a plethora of high-value collaborations. \nAs such the 14th World ADC London 2024 returns this March as a crucial touchpoint for all antibody drug conjugate developers across Europe. \nThis meeting is the place where innovation meets collaboration to drive antibody-drug conjugates forward and transform cancer therapy as we know it. Uniting 600+ industry experts and ADC newcomers\, this is a conversation you can’t afford to miss. \nTake a look at the full agenda here. \nEmbark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation\, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle. \nHere are some of the leading minds sharing translatable lessons to advance your pipeline including: \n\nAstrid Clarke\, Director\, Head of Early-Stage IND to Medicine Research\,Seagen\nColm Reddington\, Director- Global Regulatory\, Chemistry\, Manufacturing & Control\, AstraZeneca\nDaniel Milano\, Senior Director\, Process Development\, ImmunoGen\nDhiraj Gambhire\, Executive Director – Global Clinical Lead\, Enhertu\, Breast & Medical\, Daiichi Sankyo\nEmmett Scmidtt\, Vice President\, Lead External- Collaborations Project Team Global Clinical Development\, Merck & Co\nGerold Meindhart\, Vice President\, Asset & Portfolio Management\, Daiichi Sankyo\nIan Andrews\, Senior Manager\, Strategic External Development\, GlaxoSmithKline\nKurt Pike\, Senior Director\, External Innovation\, Janssen\nLarisa Stone\, Clinical Development Director\, Gilead\nLolke deHaan\, Vice President\, Toxicology\, ADC Therapeutics\nMike Liao\, Global Clinical Pharmacology Lead\, Genentech\nVenkatesh Pilla Reddy\, Senior Director\, Global PKPD & Pharmacometrics\, Eli Lilly\n\nSee the full speaker faculty and session details here. \nWhether you are pioneering ADC discoveries\, accelerating your conjugate through preclinical and clinical development\, or optimising your CMC efforts\, this is your chance to ahead of the curve with the high-quality and invaluable guidance of the supportive ADC community.
URL:https://www.pharmajournalist.com/event/14th-world-adc-london-2024/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240305
DTEND;VALUE=DATE:20240308
DTSTAMP:20260515T042027
CREATED:20231017T095950Z
LAST-MODIFIED:20231017T095950Z
UID:37964-1709596800-1709855999@www.pharmajournalist.com
SUMMARY:DNA Process Development & Manufacturing Summit
DESCRIPTION:With the cell and gene therapy industry surging\, rapid advances in mRNA-based therapies\, and the advent of DNA vaccines\, the demand for quality DNA as a critical starting and therapeutic material has skyrocketed in recent years. \nThe DNA Process Development & Manufacturing Summit is the only industry-dedicated forum to focus on topics such as DNA construct design\, sequencing technology\, and scaling production for preclinical and clinical programs\, helping to expedited IND submissions and approvals. \nDownload the official event guide here: https://ter.li/9hpxb2 \nInnovative biopharma including BioNTech\, Genentech\, AskBio\, Pfizer\, Roche\, Sanofi and more will unite in Boston to build the ultimate roadmap from plasmids through to synthetic and novel DNA innovations\, helping you advance your manufacturing capabilities for high quality therapeutics and vaccines. \nRegister your place here: https://ter.li/8kdoo7
URL:https://www.pharmajournalist.com/event/dna-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240227
DTEND;VALUE=DATE:20240301
DTSTAMP:20260515T042027
CREATED:20240111T102635Z
LAST-MODIFIED:20240111T102635Z
UID:38483-1708992000-1709251199@www.pharmajournalist.com
SUMMARY:6th Bacteriophage Therapy Summit
DESCRIPTION:The Bacteriophage Therapy Summit is the only global platform for industry-dominated phage drug developers. Actively engage with the likes of Merck\, Pfizer\, SNIPR Biome\, Locus Biosciences\, Phiogen\, AMR Action Fund and 90+ phage experts to demonstrate positive clinical data and patient outcomes. \nTake advantage of this unique opportunity to be a part of the dialogue\, meet phage leaders\, large pharma\, and venture capitalists to gain practical takeaways\, and demonstrate the clinical utility of your bacteriophage to form meaningful partnerships. \nJoin us for 3 days of unmissable content\, and accelerate your bacteriophage research into clinical\, meaningful and commercially viable therapies. \nCheck out the full event guide now: https://ter.li/jig8n0
URL:https://www.pharmajournalist.com/event/6th-bacteriophage-therapy-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240227
DTEND;VALUE=DATE:20240301
DTSTAMP:20260515T042027
CREATED:20231011T093613Z
LAST-MODIFIED:20240119T123110Z
UID:37931-1708992000-1709251199@www.pharmajournalist.com
SUMMARY:7th CAR-TCR Summit Europe
DESCRIPTION:Cell therapy continues to transform the oncology field\, and this year has also seen the translation of cell therapies’ curative potential into the autoimmune space. \nProviding your team with exclusive access to cutting-edge advances across pre-clinical platforms\, clinical advances\, and streamlined manufacturing\, the 7th CAR-TCR Summit Europe is your must-attend forum to stay at the forefront of these innovations.   \n300+ industry experts will brainstorm enhancing target discovery\, optimizing durability of response and identifying biomarkers to support recruitment\, automating production\, and accelerating analytical processes to reduce operational costs and turnaround times.   \nWith a new Biopharma & Investors Evening\, a new C-Level Think Tank\, new speakers and data from Mnemo Therpaeutics\, Cellectis\, Bambino Gesu Hospital and more\, can your team afford to miss out? \nTo know more visit: https://ter.li/6vgioi
URL:https://www.pharmajournalist.com/event/7th-car-tcr-summit-europe/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240226
DTEND;VALUE=DATE:20240229
DTSTAMP:20260515T042027
CREATED:20240213T102528Z
LAST-MODIFIED:20240213T102742Z
UID:38686-1708905600-1709164799@www.pharmajournalist.com
SUMMARY:3rd Next-Generation Conjugates Summit
DESCRIPTION:From Bristol Myers Squibb expanding their cardiovascular partnership with Avidity Biosciences’ antibody-oligonucleotide conjugate technology\, to Nurix and Seagen collaborating on a targeted protein degradation conjugate\, there is now a staggering amount of investment and collaboration in the novel conjugates space. \nAs highlighted above\, drug developers are pushing the boundaries of traditional ADCs by designing and developing novel targeting formats and payloads. Whilst the likes of VincerX Pharma\, Dyne Therapeuitcs and Alnylam are now awaiting clinical validation\, and others continue to innovate in conjugate design\, it is an exciting time for the next-generation conjugates field. \n \nCovering case-study led presentations on novel design concepts\, key translational and clinical development challenges\, and addressing challenging CMC roadblocks\, the Next-Generation Conjugates Summit is your only event uniting developers of a wide array of novel formats and payloads\, with conjugate modality types including antibody-oligonucleotide conjugates\, fragment-drug conjugates\, Targeted Radiopharmaceutical Conjugates\, small molecule-drug conjugates\, bispecific-drug conjugates and more! \nThis is the only event to unite 100+ drug developers from companies of different modality types that would not normally come together\, so make sure to join likeminded conjugate developers to learn\, collaborate and innovate and expand on the potential of conjugate drugs. \nLearn more here: https://ter.li/q5wf9x
URL:https://www.pharmajournalist.com/event/3rd-next-generation-conjugates-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240223
DTSTAMP:20260515T042027
CREATED:20240103T113819Z
LAST-MODIFIED:20240103T113819Z
UID:38417-1708387200-1708646399@www.pharmajournalist.com
SUMMARY:2nd Viral Vector Process Development & Manufacturing
DESCRIPTION:Viral Vector Process Development & Manufacturing Summit\nCreate Qualitative\, Accessible Treatments for Patients \nFollowing Ring Therapeutics’ injection of $86.5m to enhance novel viral vector capabilities\, and BMS’s viral vector facility coming online\, the viral vector market is forecasted to reach $12.8bn – not only in cell and gene therapies but also viral-vector-based vaccines and immunotherapies. \n \nWith the FDA’s fast-evolving quality assessment and lack of standard guidance\, and the continued challenge of viral vector recovery yield and purity\, the 2nd Viral Vector Process Development & Manufacturing Summit is your must-attend meeting in 2024 to help answer your burning questions to enhance process intensification capabilities while meeting regulatory agencies’ expectations. \nIn collaboration with Sarepta\, Ultragenyx\, Affinia Therapeutics\, and UCB\, we will unite 130+ pioneering viral vector up- and downstream process engineers\, MSAT\, CMC to tackle these challenges together. This is your definitive community to seek help from industry pioneers to expedite scale-up\, tech transfer\, and speed-to-clinic. Returning to Boston in February\, we are proud to expand the program into 2 tracks of content as the only industry-led\, end-to-end summit to align with your needs: \n\nDownstream process intensification\, including purification\, to improve recovery and yield\nPurity assessment to uphold GMP and product quality assessment\nDeep dive into upstream process development and cell line in relation to your viral vectors\, and assess platforming strategy\nRapid scale-up with robust analytical capabilities and improve your full:empty capsid ratio and reduce COGs\nMeet and evaluate solution providers and viral vector CDMOs\, including Lonza\, Chromatan\, Teknova\, and Genezen\, to forge long-term relationships\, ensuring tech transfer readiness\n\nIt’s worth clearing 3 days out of your office and joining this summit to leverage novel platform technologies such as continuous processing to improve viral vector manufacturing! \nTo know more visit: https://ter.li/fvlk3e
URL:https://www.pharmajournalist.com/event/2nd-viral-vector-process-development-manufacturing/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240223
DTSTAMP:20260515T042027
CREATED:20231120T110619Z
LAST-MODIFIED:20231120T110619Z
UID:38173-1708387200-1708646399@www.pharmajournalist.com
SUMMARY:6th Annual CRISPR AgBio Congress
DESCRIPTION:The 6th Annual CRISPR AgBio Congress is back on February 20-22\, 2024 (Raleigh\, NC). The dedicated congress that unites industry stakeholders across Agbiotech\, big seed\, distributors\, and investors\, to assess this new regulatory terrain\, examine recent scientific breakthroughs\, and strategize the journey of CRISPR products from editing to delivery\, field to shelf. \nDiscover the full program here. \nBack for its 6th edition\, join the likes of the Pairwise CEO\, and advisors at USDA and EPA as we: \n\nDiscover the latest on the global and US regulatory landscape\, uncover what’s new for standardizing approval processes\, and tackle regulatory compliance for your products\nUncover novel gene editing tools and CRISPR technologies\, AI\, Cas-12\, and CRISPR-enabled breeding and trait discovery tools to address unmet agricultural challenges\nExplore CRISPR product commercialization and effective market targeting strategies for rapid adoption\nTransform agriculture with sustainable crop solutions: explore alternative fuels and precision breeding for enhanced crop sustainability\nUnpick how to enhance the adaptability\, productivity\, and nutrition of orphan and non-model crops such as potatoes\, and strawberries to accelerate breeding and cut costs\n\nView your copy here to find the jam-packed agenda\, with exclusive case studies led by industry giants and regulatory bodies to help you commercialize regulatory-approved gene-edited agriculture products. \nJoin 80+ C-level leaders\, researcher heads\, Molecular Biologists\, Regulatory Experts\, and Product Developers from major seed companies\, innovative Agbiotechs\, influential academic institutions\, and regulatory bodies and be part of the conversation in 2024. \nHere’s what past attendees had to say: \n“Great quality of presentations and coherent style of participants: scientists with key roles in their company and key relevant academic researchers” – Chief Executive Officer\, Meiogenx   \n“The arrangements for the conference\, quality of speakers\, and novel ways to encourage networking were great” – Senior Director\, Yield10 Bioscience
URL:https://www.pharmajournalist.com/event/6th-annual-crispr-agbio-congress/
LOCATION:Sheraton Raleigh Hotel\, 421 South Salisbury St\, Raleigh\, NC\, 27601\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.con
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240213
DTEND;VALUE=DATE:20240216
DTSTAMP:20260515T042027
CREATED:20231123T125801Z
LAST-MODIFIED:20240117T112321Z
UID:38209-1707782400-1708041599@www.pharmajournalist.com
SUMMARY:3rd mRNA Analytical Development Summit
DESCRIPTION:100+ Technical mRNA Specialists | 35+ Expert Speakers \nAs access to faster and higher-throughput analytical methods becomes increasingly vital\, it is critical that we employ superior analytical approaches for mRNA-based therapeutics and vaccines to ensure high quality and effective drugs are approved\, whilst adhering to regulatory guidelines. \nThe 3rd mRNA Analytical Development Summit returns to Boston in February to seek and discuss new guidelines and identify a path forward with tangible best practices to ensure reliable analytical methods are guiding mRNA production\, purification and formulation optimization for approval of high quality\, compliant mRNA drugs for patients in need. \nDownload the three day program here: https://ter.li/pi54tj \n100+ Heads\, Directors and Senior Scientists of Analytical Development\, Quality Control\, CMC and Regulatory Affairs will deep dive into analytical development techniques and challenges within mRNA drug product and drug substance\, eager to glean insights into future analytical methods to safeguard regulatory submissions in 2024 and beyond. \nJoin them and register your place here: https://ter.li/d6nqe3
URL:https://www.pharmajournalist.com/event/3rd-mrna-analytical-development-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240213
DTEND;VALUE=DATE:20240216
DTSTAMP:20260515T042027
CREATED:20231101T110512Z
LAST-MODIFIED:20231101T111904Z
UID:38062-1707782400-1708041599@www.pharmajournalist.com
SUMMARY:4th Gene Therapy Comparability Summit
DESCRIPTION:As we witness a surge in later-stage clinical trials within the gene therapy industry\, the spotlight on comparability has never been brighter. That’s why we’re thrilled to announce the return of the 4th Gene Therapy Comparability Summit\, taking place in Boston\, MA\, February 13-15. \n \nThis event is your gateway to uncovering how to implement effective comparability studies to overcome strategic and technical hurdles to expedite more gene therapy approvals. \nWhat to expect at the 2024 meeting: \n\nGain valuable insights from CSL Behring\, Bayer\, Ultragenyx\, and other industry leaders on the transition to in-house manufacturing\, effective variability management\, and ensuring consistency across multiple facilities.\nExamine Sarepta’s considerations before and after receiving regulatory approval and investigate the distinctions among global regulatory agencies with insights from Novartis\, Sarepta\, and Adverum.\nStrengthen your analytical toolbox and enhance comparability studies through case studies and strategies to reduce variability with AskBio and BioMarin.\nStay ahead of the latest advancements in process development for improved characterization and analysis of AAV-gene therapies\, with a focus on minimizing process alterations\, featuring contributions from Abbvie and Spark Therapeutics.\nHarness strategic insights from cell therapy study design\, innovative analytical techniques\, and regulatory expertise to enhance your gene therapy comparability protocols\, supported by Novartis.\n\nDon’t miss this unparalleled opportunity to stay at the forefront of gene therapy comparability. Join us and gain the knowledge\, tools\, and connections to secure your gene therapy approval. \nDownload the full event guide here to view the full expert speaker line up and see who else you will meet: https://ter.li/rrefvp
URL:https://www.pharmajournalist.com/event/4th-gene-therapy-comparability-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240130
DTEND;VALUE=DATE:20240202
DTSTAMP:20260515T042027
CREATED:20240105T091432Z
LAST-MODIFIED:20240105T091432Z
UID:38450-1706572800-1706831999@www.pharmajournalist.com
SUMMARY:8th Microbiome Movement - Drug Development Summit Europe
DESCRIPTION:As Europe’s premiere microbiome conference tightly focused on the development of microbiome-based therapeutics\, this is your prime opportunity to expand your microbiome-based drug development capabilities and business potential as we aim to deliver clinical results and ensure therapeutic microbiome approval in Europe. \nNo matter what stage of development you’re focusing on\, this is your one-stop shop for microbiome-based drug development from early discovery to late-phase manufacturing! \nWhat’s New for 2024: \n\nHighlighting early-stage organisations and their novel technologies in our brand-new technology showcase where we welcome Centre for Genomic Regulation\, Recolony and Synflora to give quick fire presentations to showcase their work.\nDiscover our new enabling technologies track to learn more about the exciting artificial intelligence\, integrated -omics analysis and improved manufacturing capabilities among the other technologies that are accelerating microbiome-based drug development.\nStrengthen your regulatory understanding and enhance decision-making by uncovering global regulations to address updated SoHo frameworks\, explore considerations for engineered microbes and consolidate agencies interactions\n\nTo know more visit: https://ter.li/zi3xwf
URL:https://www.pharmajournalist.com/event/8th-microbiome-movement-drug-development-summit-europe/
LOCATION:Hotel Barceló Sants\, Pl. dels Països Catalans\, s/n\, 08014\, Barcelona\, 08014\, Spain
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240130
DTEND;VALUE=DATE:20240202
DTSTAMP:20260515T042027
CREATED:20231206T112751Z
LAST-MODIFIED:20231206T112751Z
UID:38270-1706572800-1706831999@www.pharmajournalist.com
SUMMARY:2nd Next Generation Ophthalmic Drug Delivery Summit
DESCRIPTION:The 2nd Annual Next Generation Ophthalmic Drug Delivery Summit is returning to San Francisco this January to unite 90+ device engineers\, biochemists\, preclinical and clinical experts as they discuss how they are optimizing longer-lasting and less invasive delivery to the back of the eye to reduce patient concerns and burden on healthcare systems caused by frequent drug administration. \nJoin 23+ expert speakers from the likes of AbbVie\, Boehringer Ingelheim\, Bayer\, Genentech\, Janssen\, Novartis\, and Clearside Biomedical at the only industry-dedicated event focusing on overcoming key translational challenges of developing and implementing novel delivery technology as they progress their ophthalmic pipelines to the clinic. \nTo know more visit: https://ter.li/o3pq3n
URL:https://www.pharmajournalist.com/event/2nd-next-generation-ophthalmic-drug-delivery-summit/
LOCATION:The Marker San Francisco\, 501 Geary St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240123
DTEND;VALUE=DATE:20240126
DTSTAMP:20260515T042027
CREATED:20231006T112619Z
LAST-MODIFIED:20231006T112619Z
UID:37924-1705968000-1706227199@www.pharmajournalist.com
SUMMARY:3rd mRNA-Based Therapeutics Summit Europe
DESCRIPTION:250+ mRNA Specialists | 40+ World-Class Speakers | 2 Streams of Content \nThe 3rd mRNA-Based Therapeutics Summit Europe returns to Berlin this 23rd-25th January to unite European biopharma\, to hear from the likes of BioNTech\, CureVac\, Moderna\, Pfizer\, Ethris\, Sanofi\, and regulatory insights for the MHRA and EMA. \nDownload the full brochure here: https://ter.li/1329up \nThis is your opportunity to hear the hottest content of the mRNA world\, deep diving into two content tracks on Translational Development and CMC\, a pre-conference Focus Day on AI RNA Design & Delivery\, and three immersive pre-conference workshops. \nJoin in January to understand the roadmap towards clinical success and regulatory approval\, and deliver the promise of better mRNA medicines to patients faster. \nBook your place here: https://ter.li/qu2h8f
URL:https://www.pharmajournalist.com/event/3rd-mrna-based-therapeutics-summit-europe/
LOCATION:Mecure Hotel MOA Berin\, Stephanstraße 41\, Berlin\, 10559\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR